Pricing Log in Create free account
Friday 6 November 2026 Export NVST’s income statement to Excel — free account

Envista Holdings Corporation

NVST Healthcare Medical Instruments & Supplies

Envista Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 8.32% from fiscal 2024.

Revenue
+3.22%
EPS
+1,855.6%
Free cash flow
−6.48%
Total debt
−1.13%

Quarter to September 2026, against a year earlier

24.76 0.20 −0.80%
Market cap
$4.0B
P/E
6.4×
Fwd P/E
21.5×
Dividend yield
—
F-score
7/9
Altman Z
1.59
Beneish M
−2.50
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.51
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 1 — — — — — 1 — — —
Insider Ownership 2.48%

Capital & Financial Ratios $m

Size
Market Cap 4,010.00
Revenue ttm 2,878.10
Net income ttm 633.60
Free cash flow ttm 244.60
Net debt Q 270.20
Valuation
P/E 6.36
Forward P/E 21.50
Price / sales 1.40
Forward P/S Powerpack
Price / FCF 16.42
Price / book 1.30
Financial health
Current ratio Q 2.45 (at or above 1.5: strong)
Debt / equity Q 0.46 (at or below 0.5: strong)
Interest coverage Q 66.05
Growth
Revenue growth Q +3.22% (above 0%: growing)
Operating income growth Q +796.00% (above 0%: growing)
EPS, this year +31.09% (at or above 15%: strong)
EPS, next year A +7.28%
Revenue, next year A +5.79%
EPS, past 5 yrs +6.96%
EPS, next 5 yrs A +15.14% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.5×, against a ten-year median of 2.0×; over the ten years it ranged from 1.2× in 2025 to 3.9× in 2021.
P/E against its own 10 years 2.51%
10-year low 10-year high
P/S against its own 10 years 30.68%
10-year low 10-year high
P/B against its own 10 years 56.08%
10-year low 10-year high
EV/Sales against its own 10 years 20.72%
10-year low 10-year high
EV/FCF against its own 10 years 40.47%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 940 1,069 1,212 1,159
Receivables 408 363 430 449
Inventory 259 241 288 285
Other — — — —
1,744 1,788 2,027 2,002
2023 2024 2025 Q'26
Payables 180 175 192 172
ST’ Debt 115 116 — —
Other — — — —
781 879 853 816

Compound Annual Growth %

10y 5y 3y
Sales — 7.11% 1.91%
Cash Flow — (0.58%) 14.70%
Earnings — 7.13% (42.18%)
Book Value — (3.55%) (9.62%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.35 Actual 0.40

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.32 0.38 Beat by 0.06
Q1 FY26 0.31 0.36 Beat by 0.05
Q2 FY26 0.33 0.41 Beat by 0.08
Q3 FY26 0.35 0.40 Beat by 0.05
Q4 FY26 0.41 — Reports 4 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.23 0.33 3.16 — —
’25 0.10 0.16 (0.18) 0.20 0.28
’24 0.14 (6.69) 0.05 0.01 (6.50)
’23 0.25 0.29 0.12 (1.27) (0.60)
’22 0.42 0.26 0.27 0.42 1.37
’21 0.41 0.51 0.52 0.48 1.92
’20 (0.11) (0.59) 0.22 0.64 0.20
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 706 731 692 — —
’25 617 682 670 751 2,720
’24 624 633 601 653 2,511
’23 627 662 631 646 2,567
’22 631 646 631 661 2,569
’21 613 637 607 652 2,509
’20 547 362 547 473 1,929
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) 119 78 — —
’25 0 89 79 108 276
’24 40 93 71 132 337
’23 3 75 96 102 276
’22 4 22 47 110 183
’21 17 121 88 136 362
’20 (62) 5 148 193 284
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) 105 64 — —
’25 (5) 76 68 92 231
’24 29 86 63 124 303
’23 (14) 61 77 100 224
’22 (16) 10 21 95 110
’21 8 101 82 127 319
’20 (76) (3) 135 186 242
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2,785 2,811 2,845 2,285 1,929 2,509 2,569 2,567 2,511 2,720 2,878 (0.3%) 2,877 2,982 3,102 +4.5%
Gross margin, % 57.92 57.68 56.31 59.05 54.68 56.86 57.41 56.13 54.68 54.67 55.88 (3.3) pt
EBT 402 387 301 234 (20) 255 284 (55) (1,085) 177 684 (8.7%)
EBT margin, % 14.43 13.76 10.59 10.23 (1.04) 10.14 11.05 (2.14) (43.20) 6.52 23.78 (7.9) pt
Net income 272 301 231 218 33 341 243 (100) (1,119) 47 634 (17.7%)
Per share, $
Per share, $ Revenue 17.52 21.98 22.24 16.78 12.09 15.56 15.77 15.38 14.58 16.19 17.90 (0.9%)
Earnings 1.71 2.35 1.80 1.60 0.21 2.11 1.49 (0.60) (6.50) 0.28 3.93 (18.2%)
Cash flow 2.62 2.81 3.13 2.92 1.78 2.24 1.12 1.65 1.95 1.64 1.88 (5.1%)
Capex 0.00 (0.38) (0.56) (0.56) (0.27) (0.27) (0.44) (0.31) (0.20) (0.27) (0.36) n/m
Free cash flow 2.62 2.43 2.56 2.36 1.51 1.98 0.68 1.34 1.76 1.37 1.52 (6.9%)
Book value 0.00 0.00 37.74 26.01 23.31 25.17 25.83 25.01 17.04 18.49 19.21 n/m
Shares, m 159 128 128 136 160 161 163 167 172 168 164 +0.6%
Valuation, ×
Valuation, × P/E 5.52 5.52 5.52 18.44 168.65 21.25 22.79 0.00 0.00 77.54 6.36 32.5
P/S 0.00 0.00 0.00 1.77 2.79 2.90 2.15 1.57 1.32 1.34 1.40 1.4
P/B 0.74 0.74 0.74 1.14 1.45 1.79 1.32 0.96 1.13 1.17 1.30 1.1
EV/Sales 0.00 0.00 0.00 2.25 3.26 2.99 2.45 1.79 1.45 1.47 1.53 1.6
EV/FCF 8.96 8.96 8.96 16.03 26.04 23.57 57.17 20.55 12.04 17.32 18.00 20.0
Cash, $m
Cash, $m Operating cash flow 417 359 400 398 284 362 183 276 337 276 302 (4.5%)
Capex (49) (49) (72) (76) (42) (43) (72) (52) (34) (45) (57) (1.0%)
Free cash flow 417 310 328 321 242 319 110 224 303 231 245 (6.4%)
Balance, $m
Balance, $m Working capital — 167 146 293 (94) 628 188 963 910 1,174 1,186 +27.6%
Net debt — — — 1,114 906 242 774 573 325 237 270 (22.8%)
Shareholders’ equity — — 4,826 3,543 3,721 4,058 4,207 4,174 2,935 3,106 3,089 (6.1%)
Returns, %
Returns, % ROA 0.00 5.09 7.90 3.63 0.51 5.06 3.69 (1.52) (18.71) 0.85 11.26 +0.9 pt
ROIC — 0.00 3.86 3.16 0.59 4.45 4.01 0.41 (19.90) 4.04 13.61 +4.0 pt
ROE 0.00 6.14 4.70 5.20 0.92 8.75 5.88 (2.39) (31.47) 1.56 20.52 +1.6 pt
People
People Employees — — 12,800 12,500 12,400 11,200 12,700 12,800 12,300 12,000 — (0.9%)
Revenue/emp, $m 0.00 0.00 0.22 0.18 0.16 0.22 0.20 0.20 0.20 0.23 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

Envista Holdings Corporation vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TFX Teleflex Incorporated $6.5B — (loss-making) 37.4× +28.88% (above 0%: growing) −17.33% (below 0%: shrinking) +220.14% (above 0%: growing) 58.16% 12.77% Compare
MMSI Merit Medical Systems, Inc. $5.4B 33.2× 30.7× +8.35% (above 0%: growing) +50.53% (above 0%: growing) +50.18% (above 0%: growing) 48.20% 14.12% Compare
MMED MiniMed Group, Inc. $5.1B — (loss-making) 27.8× — n/m −13.92% (below 0%: shrinking) 55.16% 0.47% Compare
ICUI ICU Medical, Inc. $4.2B 69.3× 48.8× +4.37% (above 0%: growing) n/m +292.20% (above 0%: growing) 41.89% 9.34% Compare
NVST Envista Holdings Corporation $4.0B 6.4× 21.5× +3.22% (above 0%: growing) n/m −6.48% (below 0%: shrinking) 57.93% 74.50%
PLSE Pulse Biosciences, Inc $3.9B — (loss-making) — (loss-making) +359.30% (above 0%: growing) n/m −1,180.54% (below 0%: shrinking) 51.65% (6,149.87%) Compare
STVN Stevanato Group S.p.A. $3.6B 22.4× 30.2× +5.91% (above 0%: growing) +17.53% (above 0%: growing) +4,089.92% (above 0%: growing) 29.12% 18.51% Compare
WRBY Warby Parker Inc. $3.2B 434× 208× +10.40% (above 0%: growing) −20.00% (below 0%: shrinking) −30.28% (below 0%: shrinking) 54.41% 1.45% Compare
ATRC AtriCure, Inc. $3.1B 199× 573× +15.03% (above 0%: growing) n/m −0.73% (below 0%: shrinking) 77.27% 2.82% Compare
Median of peers $4.0B 69.3× 37.4× +10.40% +0.10% +24.73% 53.03% 6.08%

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 7 April 2026

Ownership

Directors and executive officers, together less than 1%
The Vanguard Group 10.50%
BlackRock, Inc. 9.70%
Ariel Investments, LLC 7.00%
Morgan Stanley 6.20%
Dimensional Fund Advisors 5.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Envista Holdings Corporation (NVST) Latest News

5 Nov

Impact 3 · · Zacks
Impact 3 · · Simply Wall St.
Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · Simply Wall St.
Impact 3 · · MarketBeat transcript
Impact 3 · · GuruFocus.com

4 Nov

Impact 3 · · StockStory
Impact 3 · · PR Newswire

28 Oct

Impact 3 · · Zacks
Impact 3 · · Zacks

27 Oct

Impact 3 · · PR Newswire

15 Oct

Impact 3 · · ACCESS Newswire

1 Oct

Impact 3 ·

21 Sep

Impact 3 ·

25 Aug

Impact 3 ·

14 Aug

Impact 3 ·
Impact 3 ·

12 Aug

Impact 3 · · The Motley Fool transcript

9 Aug

Impact 4 ·

8 Aug

Impact 3 · · MarketBeat

6 Aug

Impact 4 ·
Impact 3 · · Moby transcript

5 Aug

Impact 3 ·
Impact 3 ·
Impact 3 ·

13 Jul

Impact 3 ·

3 Jun

Impact 3 · · Zacks

22 May

Impact 3 · · Simply Wall St.

13 May

Impact 4 · · MarketBeat

NVST metrics, ten years each

stockrow.com/NVST · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com